A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lance Leopold, M.D.
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Bendigo, Australia
- Facility name not stated
Heidelberg, Australia
- Facility name not stated
Herston, Australia
- Facility name not stated
Milton, Australia
- Facility name not stated
Randwick, Australia
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Izhevsk, Russia
- Facility name not stated
Krasnodar, Russia
- Facility name not stated
Kursk, Russia
- Facility name not stated
Moscow, Russia
- Facility name not stated
Orenburg, Russia
- Facility name not stated
Saint Petersburg, Russia
- Facility name not stated
Ufa, Russia
- Facility name not stated
Yekaterinburg, Russia
- Facility name not stated
Chernivtsi, Ukraine
- Facility name not stated
Dnipro, Ukraine
- Facility name not stated
Kharkiv, Ukraine
- Facility name not stated
Lutsk, Ukraine
- Facility name not stated
Bebington, United Kingdom
- Facility name not stated
Cardiff, United Kingdom
- Facility name not stated
Edinburgh, United Kingdom
- Facility name not stated
Glasgow, United Kingdom
- Facility name not stated
Keighley, United Kingdom
- Facility name not stated
Leeds, United Kingdom
- Facility name not stated
Liverpool, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Nottingham, United Kingdom
- Facility name not stated
Oxford, United Kingdom
- Facility name not stated
West Midlands, United Kingdom
- Facility name not stated
La Jolla, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
Evanston, Illinois, United States
- Facility name not stated
Joliet, Illinois, United States
- Facility name not stated
Iowa City, Iowa, United States
- Facility name not stated
Covington, Louisiana, United States
- Facility name not stated
Baltimore, Maryland, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2012
- Primary completion
- 23 Oct 2014
- Completion
- 23 Oct 2014
- Last update posted
- 11 Mar 2019
- Registered enrollment
- 83
- Registry id
- NCT01685255
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.